Effect of Calcium Carbonate for Reduction of Serum Fibroblast Growth Factor 23 (FGF 23) in Chronic Kidney Disease Stage 3

Phase 4

Recruiting

• Conditions: Chronic kidney disease stage 3; chronic kidney disease stage 3; calcium carbonate; phosphate binder; Fibroblast growth factor 23

• Registration Number: TCTR20150220001
• Lead Sponsor: Siriraj Research and Development Fund Type 2

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2015-02-20
• Study Completion: 2016-02-19
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 75

Inclusion Criteria

Chronic kidney disease stage 3 defined by estimated GFR using CKD-EPI formula
Age >18 years old
FGF-23 > 100 RU/m

Exclusion Criteria

1. Serum albumin corrected calcium > 9.6 mg/dL or serum phosphate > 4.5 mg/dL or intact PTH > 65 pg/mL
2. History of symptomatic hypocalcemia
3. History of calculi in genitourinary system
4. Primary hyperparathyroidism
5. History of thyroidectomy, parathyroidectomy, or radiation of head and neck
6. Patients prescribed drugs interfering vitamin D and/or bone metabolism, for example, corticosteroids, phenytoin, calcimimetics, calcineurin inhibitor, etc.
6. Patients diagnosed osteoporosis and treated with bislphosphonates and/ or estrogen derivatives
7. Pregnancy

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
FGF23 9 months pg/mL by Human FGF-23 (C-Term) ELISA Kit (Immunotopic, CA, USA)

Secondary Outcome Measures

Name	Time	Method
hypercalcemia 9 months mg/d